Compare Lufax Holding Ltd (LU) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Novavax Inc — how do they compare? Lufax Holding Ltd trades at $1.56 (market cap $2.41B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Lufax Holding Ltd is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| LU | NVAX | |
|---|---|---|
Market Cap | $2.41B | $1.30B |
Sector | Technology | Health |
52-Week High | $4.40 | $11.19 |
52-Week Low | $1.23 | $6.22 |
Enterprise Value | — | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $1.50, up 0.67% on the day, with a neutral technical signal and bearish moving averages. The stock shows deep value on price-to-sales (0.42) and price-to-book (0.12) ratios but faces profitability challenges with a -9.08% net margin and negative ROE. Recent earnings misses and a securities class action lawsuit filed in May 2026 create headwinds, though analyst consensus remains 69% buy-rated.
The outlook is cautious due to litigation overhangs and persistent losses, but low valuations may attract value investors if operational improvements materialize. Key risks include legal liabilities and execution on turning profitability; upside depends on management's ability to stabilize earnings amid competitive pressures in Chinese financial services.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
